{
  "trial_id": "NCT04884191",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, gender, race, ECOG performance status, DIPSS risk score, prior ruxolitinib treatment duration, spleen size, total symptom score (TSS), peripheral blast count, absolute neutrophil count, liver function tests (AST, ALT, bilirubin), renal function (creatinine), coagulation function (PT/INR, PTT, TT), left ventricular ejection fraction, history of splenectomy, history of splenic irradiation, use of anticoagulation or antiplatelet agents, use of CYP3A4 inhibitors or inducers, use of medications that prolong QTc interval, recent experimental therapy, recent significant bleeding history, history of cardiac conditions, QTc interval, gastrointestinal or metabolic conditions, other malignancies, intercurrent illnesses, HIV status, hepatitis status, pregnancy or lactation status.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "gender"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ],
        [
          "ECOG PS",
          "ECOG performance status"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male",
        "BMI"
      ],
      "remaining_candidate_features": [
        "DIPSS risk score",
        "prior ruxolitinib treatment duration",
        "spleen size",
        "total symptom score (TSS)",
        "peripheral blast count",
        "absolute neutrophil count",
        "liver function tests (AST, ALT, bilirubin)",
        "renal function (creatinine)",
        "coagulation function (PT/INR, PTT, TT)",
        "left ventricular ejection fraction",
        "history of splenectomy",
        "history of splenic irradiation",
        "use of anticoagulation or antiplatelet agents",
        "use of CYP3A4 inhibitors or inducers",
        "use of medications that prolong QTc interval",
        "recent experimental therapy",
        "recent significant bleeding history",
        "history of cardiac conditions",
        "QTc interval",
        "gastrointestinal or metabolic conditions",
        "other malignancies",
        "intercurrent illnesses",
        "HIV status",
        "hepatitis status",
        "pregnancy or lactation status"
      ]
    },
    "processed-gen-response": "Age, gender, race, ECOG performance status, DIPSS risk score, prior ruxolitinib treatment duration, spleen size, total symptom score (TSS), peripheral blast count, absolute neutrophil count, liver function tests (AST, ALT, bilirubin), renal function (creatinine), coagulation function (PT/INR, PTT, TT), left ventricular ejection fraction, history of splenectomy, history of splenic irradiation, use of anticoagulation or antiplatelet agents, use of CYP3A4 inhibitors or inducers, use of medications that prolong QTc interval, recent experimental therapy, recent significant bleeding history, history of cardiac conditions, QTc interval, gastrointestinal or metabolic conditions, other malignancies, intercurrent illnesses, HIV status, hepatitis status, pregnancy or lactation status."
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, DIPSS risk score, Prior ruxolitinib treatment duration, Palpable splenomegaly, Total Symptom Score (TSS), Eastern Cooperative Oncology Group (ECOG) performance status, Peripheral blast count, Absolute neutrophil count, Liver function tests (AST, ALT, bilirubin), Renal function (creatinine), Coagulation function (PT/INR, PTT, TT), Left ventricular ejection fraction,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race (NIH/OMB)",
          "Race/Ethnicity"
        ],
        [
          "ECOG PS",
          "Eastern Cooperative Oncology Group (ECOG) performance status"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "BMI"
      ],
      "remaining_candidate_features": [
        "Region of Enrollment",
        "DIPSS risk score",
        "Prior ruxolitinib treatment duration",
        "Palpable splenomegaly",
        "Total Symptom Score (TSS)",
        "Peripheral blast count",
        "Absolute neutrophil count",
        "Liver function tests (AST, ALT, bilirubin)",
        "Renal function (creatinine)",
        "Coagulation function (PT/INR, PTT, TT)",
        "Left ventricular ejection fraction"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, DIPSS risk score, Prior ruxolitinib treatment duration, Palpable splenomegaly, Total Symptom Score (TSS), Eastern Cooperative Oncology Group (ECOG) performance status, Peripheral blast count, Absolute neutrophil count, Liver function tests (AST, ALT, bilirubin), Renal function (creatinine), Coagulation function (PT/INR, PTT, TT), Left ventricular ejection fraction"
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, DIPSS Risk Score, Prior Ruxolitinib Treatment Duration, Spleen Length, Total Symptom Score, MPN-SAF TSS 2.0, ECOG Performance Status, Peripheral Blast Count, Absolute Neutrophil Count, Liver Transaminases, Direct Bilirubin, Creatinine, Prothrombin Time/International Normalized Ratio, Partial Thromboplastin Time, Thrombin Time, Left Ventricular Cardiac Ejection Fraction.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race (NIH/OMB)",
          "Race/Ethnicity"
        ],
        [
          "ECOG PS",
          "ECOG Performance Status"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "BMI"
      ],
      "remaining_candidate_features": [
        "Region of Enrollment",
        "DIPSS Risk Score",
        "Prior Ruxolitinib Treatment Duration",
        "Spleen Length",
        "Total Symptom Score",
        "MPN-SAF TSS 2.0",
        "Peripheral Blast Count",
        "Absolute Neutrophil Count",
        "Liver Transaminases",
        "Direct Bilirubin",
        "Creatinine",
        "Prothrombin Time/International Normalized Ratio",
        "Partial Thromboplastin Time",
        "Thrombin Time",
        "Left Ventricular Cardiac Ejection Fraction"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, DIPSS Risk Score, Prior Ruxolitinib Treatment Duration, Spleen Length, Total Symptom Score, MPN-SAF TSS 2.0, ECOG Performance Status, Peripheral Blast Count, Absolute Neutrophil Count, Liver Transaminases, Direct Bilirubin, Creatinine, Prothrombin Time/International Normalized Ratio, Partial Thromboplastin Time, Thrombin Time, Left Ventricular Cardiac Ejection Fraction."
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ethnicity, weight, height, body mass index (BMI), DIPSS risk score, ECOG performance status, peripheral blast count, absolute neutrophil count, liver transaminases (AST/SGOT and ALT/SGPT), direct bilirubin, creatinine, prothrombin time (PT)/international normalized ratio (INR), partial thromboplastin time (PTT), thrombin time (TT), left ventricular cardiac ejection fraction, palpable splenomegaly, TSS, MPN-SAF TSS 2.0, prior ruxolitinib treatment duration and dosage, prior ruxolitinib response.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ],
        [
          "BMI",
          "body mass index (BMI)"
        ],
        [
          "ECOG PS",
          "ECOG performance status"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male"
      ],
      "remaining_candidate_features": [
        "ethnicity",
        "weight",
        "height",
        "DIPSS risk score",
        "peripheral blast count",
        "absolute neutrophil count",
        "liver transaminases (AST/SGOT and ALT/SGPT)",
        "direct bilirubin",
        "creatinine",
        "prothrombin time (PT)/international normalized ratio (INR)",
        "partial thromboplastin time (PTT)",
        "thrombin time (TT)",
        "left ventricular cardiac ejection fraction",
        "palpable splenomegaly",
        "TSS",
        "MPN-SAF TSS 2.0",
        "prior ruxolitinib treatment duration and dosage",
        "prior ruxolitinib response"
      ]
    },
    "processed-gen-response": "Age, sex, race, ethnicity, weight, height, body mass index (BMI), DIPSS risk score, ECOG performance status, peripheral blast count, absolute neutrophil count, liver transaminases (AST/SGOT and ALT/SGPT), direct bilirubin, creatinine, prothrombin time (PT)/international normalized ratio (INR), partial thromboplastin time (PTT), thrombin time (TT), left ventricular cardiac ejection fraction, palpable splenomegaly, TSS, MPN-SAF TSS 2.0, prior ruxolitinib treatment duration and dosage, prior ruxolitinib response."
  }
}